» Articles » PMID: 22107991

Genotoxicity Testing of Low Molecular Weight Fucoidan from Brown Seaweeds

Overview
Date 2011 Nov 24
PMID 22107991
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Fucoidan extracts from brown seaweed have anticoagulant, antithrombotic, and antiviral activities. Low molecular weight fucoidan (LMF) obtained by acid hydrolysis of high molecular weight fucoidan showed more favorable bioactivity. Despite extensive work on LMF bioactivities, detailed studies on the genotoxicity of LMF have not been conducted. As part of a safety evaluation, the potential genotoxicity of LMF was evaluated using a standard battery of tests (bacterial reverse mutation assay, chromosomal aberrations assay, and mouse micronucleus assay). The LMF was determined not to be genotoxic under the conditions of the reverse mutation assay, chromosomal aberrations assay, or mouse micronucleus assay. In a reverse mutation assay using four Salmonella typhimurium strains and Escherichia coli, LMF did not increase the number of revertant colonies in any tester strain regardless of metabolic activation by S9 mix, and did not cause chromosomal aberration in short tests with the S9 mix or in the continuous (24 h) test. A bone marrow micronucleus test in ICR mice dosed by oral gavage at doses up to 2000 mg/kg body weight/day showed no significant or dose-dependent increases in the frequency of micronucleated polychromatic erythrocytes. Use of LMF is presently expected to be safe, as anticipated intake is small compared to doses administered in the genotoxicity assays and may prove to be a useful bioactive agent after further toxicity research.

Citing Articles

Fucoidan's Molecular Targets: A Comprehensive Review of Its Unique and Multiple Targets Accounting for Promising Bioactivities Supported by In Silico Studies.

Zayed A, Al-Saedi D, Mensah E, Kanwugu O, Adadi P, Ulber R Mar Drugs. 2024; 22(1).

PMID: 38248653 PMC: 10820140. DOI: 10.3390/md22010029.


The Neuropharmacological Evaluation of Seaweed: A Potential Therapeutic Source.

Jannat K, Balakrishnan R, Han J, Yu Y, Kim G, Choi D Cells. 2023; 12(22).

PMID: 37998387 PMC: 10670678. DOI: 10.3390/cells12222652.


Fucoidan alleviates the hepatorenal syndrome through inhibition organic solute transporter α/β to reduce bile acids reabsorption.

Zhao X, Yang T, Zhou J, Chen Y, Shen Q, Zhang J Curr Res Pharmacol Drug Discov. 2023; 5:100159.

PMID: 37416532 PMC: 10320405. DOI: 10.1016/j.crphar.2023.100159.


Possibilities of Fucoidan Utilization in the Development of Pharmaceutical Dosage Forms.

Citkowska A, Szekalska M, Winnicka K Mar Drugs. 2019; 17(8).

PMID: 31387230 PMC: 6722496. DOI: 10.3390/md17080458.


Promoting Wound Healing Using Low Molecular Weight Fucoidan in a Full-Thickness Dermal Excision Rat Model.

Park J, Choi S, Park S, Lee Y, Park J, Song P Mar Drugs. 2017; 15(4).

PMID: 28387729 PMC: 5408258. DOI: 10.3390/md15040112.